Breast care (Basel, Switzerland)最新文献

{"title":"Parotid Gland Metastasis of Breast Cancer: Case Report and Review of the Literature.","authors":"Katsutoshi Ando,&nbsp;Norio Masumoto,&nbsp;Masaaki Sakamoto,&nbsp;Kou Teraoka,&nbsp;Takako Suzuki,&nbsp;Terumasa Kurihara,&nbsp;Satoko Abe,&nbsp;Mitsuhiro Tozaki,&nbsp;Eisuke Fukuma,&nbsp;Kazuei Hoshi","doi":"10.1159/000335222","DOIUrl":"https://doi.org/10.1159/000335222","url":null,"abstract":"<p><p>BACKGROUND: Parotid gland metastasis in breast cancer is extremely rare, and only 14 cases have been reported between 1982 and 2010. CASE REPORT: A 67-year-old female patient was diagnosed with invasive lobular carcinoma of the left breast. Although clinical staging was T1N3M1 (stage IV), the tumor experienced a complete response to chemotherapy. We therefore performed a mastectomy followed by radiotherapy, and continued administration of trastuzumab. However, 11 months later, the patient complained of a swelling in the left parotid gland. Histology following a partial parotidectomy revealed a parotid gland metastasis from the breast. CONCLUSION: Treatment with capecitabine in addition to trastuzumab, which is one of the strategies applied in HER2-positive breast cancer, was effective in our patient. Analysis of the 14 cases of parotid gland metastasis from the breast reported between 1982 and 2010 revealed that the metastasis may occur not by direct lymphatic but by hematogenous spread.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"471-473"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335222","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40166608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nipple Retractor to Correct Inverted Nipples.","authors":"Xiao Long,&nbsp;Ru Zhao","doi":"10.1159/000335221","DOIUrl":"https://doi.org/10.1159/000335221","url":null,"abstract":"<p><p>BACKGROUND: Inverted nipples are a common problem and a challenging clinical condition to repair. Multiple methods have been reported to correct inverted nipples, most of which will destroy breastfeeding function. PATIENTS AND METHODS: We have designed a simple nipple retractor to correct inverted nipples. A total of 53 patients with 95 inverted nipples underwent an operation in which the nipples were retracted into a normal position and fixated with the nipple retractor and wires under local anesthesia. Nipple retractors were to be worn for 6 months. Postoperatively, the patients were invited to follow-up on the 1st day, the 7th day, after 1 month, 3 months and 6 months, and yearly thereafter. Wire adjustments were performed as needed. Mean follow-up was 11.9 months (range 8-18 months). RESULTS: Improvement occurred in all patients and was sustained in all cases throughout the follow-up period. The total complication rate was 5.26% (5/95). The main complications included depigmentation (2.11%, 2/95), areolar ulcer (2.11%, 2/95), and wire dislocation (1.05%, 1/95). CONCLUSION: The nipple retractor is a simple tool with which severely inverted nipples can be successfully corrected with a low complication rate. Close follow-up and careful postoperative care are important to avoid complications.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"463-465"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40166613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Treatment of Breast Cancer.","authors":"Michael Untch,&nbsp;Gunter von Minckwitz","doi":"10.1159/000335444","DOIUrl":"https://doi.org/10.1159/000335444","url":null,"abstract":"","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"417"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40167228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer-Associated Thrombotic Microangiopathy.","authors":"Anne C Regierer,&nbsp;Dagmar Kuehnhardt,&nbsp;Carsten-Oliver Schulz,&nbsp;Bernd Flath,&nbsp;Christian F Jehn,&nbsp;Christian W Scholz,&nbsp;Kurt Possinger,&nbsp;Jan Eucker","doi":"10.1159/000335201","DOIUrl":"https://doi.org/10.1159/000335201","url":null,"abstract":"<p><p>BACKGROUND: Thrombotic microangiopathy (TMA) is defined as thrombocytopenia and microangiopathic hemolytic anemia. Cancer-associated TMA, a rare but fatal condition, seems an entity distinct from classical thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS). PATIENTS AND METHODS: All patients with breast cancer-associated TMA treated at our institution between 2003 and 2008 were analyzed retrospectively. To elucidate pathophysiological mechanisms, we measured the serum activity of the metalloprotease ADAMTS13. RESULTS: 8 patients were identified. All showed bone marrow infiltration of breast cancer as well as thrombocytopenia, schistocytes, and hemolytic anemia. ADAMTS13 activity was mildly decreased in 4/6 patients (20-108%, normal range 30-120%), but none showed severely low levels as is characteristic of classical TTP. 6 patients were treated with anthracycline-containing fractionated chemotherapy, 5/6 patients experienced partial response. Overall survival was 13 months. Fractionated chemotherapy was well tolerated. CONCLUSIONS: Cancer-associated TMA has an underlying mechanism different from classical TTP. While bone marrow infiltration might be of major relevance, ADAMTS13 deficiency seems to be an epiphenomenon. Fractionated chemotherapy resulted in higher remission rates and comparatively long survival.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"441-445"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40167232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases.","authors":"Tingting Liu,&nbsp;Zhongsheng Tong,&nbsp;Lihong He,&nbsp;Li Zhang","doi":"10.1159/000335204","DOIUrl":"https://doi.org/10.1159/000335204","url":null,"abstract":"Background: The aim of this study was to investigate the clinicopathologic characteristics, therapy methods, and prognosis of male breast cancer. Patients and Methods: We retrospectively analyzed the clinicopathological characteristics, recurrence or metastasis, and survival information of 87 male breast cancer patients. Statistical analysis included the Kaplan-Meier method to analyze survivals, log-rank to compare curves between groups, and Cox regression for multivariate prognostic analysis. A p value of <0.05 was considered statistically significant. Results: 5-year disease free survival (DFS) and 5-year overall survival (OS) were 66.3 and 77.0%, respectively. Monofactorial analysis showed tumor size, stage, lymph node involvement, and adjuvant chemotherapy to be prognostic factors with regard to 5-year DFS and 5-year OS. Multivariate Cox regression analysis showed tumor size, stage, and adjuvant chemotherapy to be independent prognostic factors with regard to 5-year DFS and 5-year OS. Conclusion: Male breast cancer has a lower incidence rate and poor prognosis. Invasive ductal carcinoma is the main pathologic type. Operation-based combined therapy is the standard care for these patients. Tumor size, stage, and adjuvant chemotherapy are independent prognostic factors. More emphasis should be placed on early diagnosis and early therapy, and adjuvant chemotherapy may improve survival.","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"446-451"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40167233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature.","authors":"Ingo Gottschalk,&nbsp;Christoph Berg,&nbsp;Nadia Harbeck,&nbsp;Rüdiger Stressig,&nbsp;Peter Kozlowski","doi":"10.1159/000335202","DOIUrl":"https://doi.org/10.1159/000335202","url":null,"abstract":"<p><p>Some drugs are known for their fetal nephrotoxicity and should be avoided during pregnancy. We report on a pregnant woman suffering from breast cancer who received a weekly neoadjuvant trastuzumab (Herceptin(®)) therapy from 15 weeks of gestation onward, in addition to a 3-weekly carboplatin/docetaxel chemotherapy. Fetal renal insufficiency with anhydramnios and missing visualization of the fetal bladder developed at 21 weeks. After discontinuation of trastuzumab and repeated instillation of amniotic fluid, the amount of amniotic fluid remained stable after 24 weeks of gestation. After caesarean section at 34 weeks because of fetal growth restriction, the renal function of the neonate was normal postnatally. In accordance with the current literature, our case shows a reversible adverse effect of trastuzumab on the fetal renal function and confirms the current recommendation that trastuzumab in pregnancy should be avoided. In pregnancies exposed to trastuzumab, treatment should be discontinued and the fetus should be closely monitored, with particular attention to the amniotic fluid and the fetal bladder volume, as these reflect fetal renal function.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"475-478"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40166610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normal Breastfeeding after Breast Reconstruction in a Patient with Poland's Syndrome.","authors":"Eveline B Madeira,&nbsp;Júlio C Queiroz de França,&nbsp;Benedito de Sousa Almeida Filho,&nbsp;Ana L Nascimento Araújo,&nbsp;Sabas C Vieira","doi":"10.1159/000335223","DOIUrl":"https://doi.org/10.1159/000335223","url":null,"abstract":"<p><p>BACKGROUND: Poland's syndrome is a rare congenital non-inherited anomaly that usually manifests itself during adolescence and is characterized by absence or deficient development of one of the breasts. To our knowledge, no case of breastfeeding after reconstruction surgery in patients with Poland's syndrome has been described. CASE REPORT: A 22-year-old female patient with Poland's syndrome underwent breast reconstruction. The procedure performed consisted of rotation of a myocutaneous flap harvested from the ipsilateral latissimus dorsi muscle, which was subsequently attached to the anterior thoracic wall to create a pouch and place a 300-ml round textured cohesive silicone gel-filled breast implant. 5 years later the patient got pregnant, and 1 year after delivery she is still breastfeeding normally with both breasts. CONCLUSION: Reconstruction surgery with the latissimus dorsi muscle and a prosthesis was shown to be a potential and safe solution to achieve improvement of breast symmetry and to provide confidence and comfort in relation to self-image and, moreover, the ability to breastfeed.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"479-481"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40166611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Breast Cancer Biomarkers.","authors":"Angelo Paradiso,&nbsp;Rosella Silvestrini,&nbsp;Gennaro Chiappetta","doi":"10.1159/000309176","DOIUrl":"https://doi.org/10.1159/000309176","url":null,"abstract":"The enormous technological developments characterizing the last decades of cancer research made possible the interpretation of several biological phenomena peculiar of cancer cells. However, after many efforts in the search for clinical application of this know-how in terms of new biomolecular markers for risk, prognosis, and prediction of therapeutic efficacy still only few examples of their utilization in clinical practice are available. One reason for this could be the lack of translation into routine practice; other frequently cited reasons are the low quality of the validation studies performed so far [1] and the need for an optimization of the process leading the biomarker from basic research to clinical practice [2]. \u0000 \u0000Aware of this situation, the Italian Ministry of Health in 2007 supported the development of a national concerted action aimed at developing a specific pathway for ‘analytical and clinical validation of new biomarkers for cancer diagnosis and outcome prediction'. The supported action clustered 37 national research teams, involved in different biomarker studies and interested in generating a coordinating body where expertise in methodologies, statistical analysis, quality control, and biological resources to perform validation studies for new cancer biomarkers were concentrated. The action, coordinated by the National Cancer Institute (NCI) – Istituto Tumori Bari, started in 2007 and activated 7 projects, each of which focused on specific tumors and disease-specific biomarker studies [2]. \u0000 \u0000 \u0000One of these, the project ‘biomarkers of female cancers', was aimed at promoting the development of technologies for isolating and characterizing circulating cancer cells in breast cancer patients, and validating the use of a panel of markers for circulating cancer cell detection to improve the accuracy of cancer staging, prognosis, and as a rapid assessment of therapeutic response. Several groups are involved in this project: \u0000 \u0000 \u00001) \u0000 \u0000The Unit of the Istituto Nazionale Tumori Fondazione Pascale, Naples (Dr. G. Chiappetta), analyzes the high mobility group A (HMGA) protein overexpression in the serum of patients with operable breast cancer, patients with metastatic breast cancer, and subjects without evidence of cancer. HMGA proteins (HMGAla, HMGAlb, HMGA2) are an abundant class of nuclear factors that play an important role in regulating the transcription of a large number of genes [3]. Aim of this project is to validate these proteins as markers for early cancer cell detection and to improve the accuracy of cancer staging and prognosis, possibly leading to a rapid assessment of therapeutic response. \u0000 \u0000 \u00002) \u0000 \u0000The Unit of the Istituto Nazionale per la Ricerca sul Cancro of Genoa (Dr. M. Romani), examines the potential application of circulating nucleic acids, both DNA and RNA, as a breast cancer biomarker for early diagnosis and for the evaluation of the patients’ prognosis. \u0000 \u0000 \u00003) \u0000 \u0000The Unit of the Casa Sollievo della Sofferenza","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"60-61"},"PeriodicalIF":2.1,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000309176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40073945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Therapy in Breast Cancer.","authors":"Andreas Schneeweiss","doi":"10.1159/000315676","DOIUrl":"https://doi.org/10.1159/000315676","url":null,"abstract":"Due to an increased knowledge on how to run well-designed clinical trials, development of cancer drugs has evolved substantially, including cytotoxic agents, endocrine agents and new-generation targeted drugs. However, the major aims are still to register and establish new drugs for broad groups of rather unselected patients based on crude conventional classification systems. As in general only a small group of patients experiences an advantage, current trials must have large sample sizes to be able to detect small efficacy differences. Despite this, significant achievements have been made for breast cancer with the use of new drugs in the metastatic and the adjuvant setting [1, 2]. These improvements, however, have been paid for by overtreatment and undertreatment of large cohorts of patients. \u0000 \u0000In parallel, there have been remarkable improvements in molecular and functional understanding of normal breast tissue development and breast cancer. Breast cancer is no longer one disease entity. Retrospective RNA expression profiling and reverse transcriptase polymerase chain reaction (RT-PCR) based studies have defined distinct subgroups with different prognoses requiring different clinical management [3,4,5,6,7,8]. Therefore, it is time to finally leave the ‘one fits all’ strategy. Two signatures, which are currently tested in the Microarray in Node-Negative Disease May Avoid Chemotherapy Trial (MINDACT) and the Trial Assigning Individualized Options for Treatment (TAILORx) trial, will hopefully help to reduce adjuvant cytotoxic overtreatment in the near future. Given the huge amount of new targeted drugs currently in preclinical and clinical development as outlined by the comprehensive overview of Joachim Bischoff and Atanas Ignatov in this issue of Breast Care [9], it is time to prospectively integrate more molecular and biologic knowledge into oncological study designs. New targeted drugs will potentially only be effective in small subgroups of breast cancer patients based on prospectively proven marker signatures or functional characteristics rather than on morphology or single markers alone. \u0000 \u0000Currently targeted drug selection in breast cancer is exclusively based on estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor (HER2) expression mainly of the primary tumor, even if metastatic disease is actually treated. Retrospective data indicate discordance regarding those factors between primary tumors and corresponding metastatic lesions in up to 44% of patients, which would even require alterations during palliative treatment [10,11,12,13]. For better patient selection this indicates the need for prospective target evaluation not only in the primary tumor but also in metastatic lesions. \u0000 \u0000In addition, for treatment evaluation it is essential to obtain data on whether the targeted drug administered actually reaches the target and results in inhibition of function. This strategy requires repeated biopsies.","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"132-133"},"PeriodicalIF":2.1,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000315676","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40074908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Mobility Group A (HMGA) Proteins and Breast Cancer.","authors":"Silvia Peluso,&nbsp;Gennaro Chiappetta","doi":"10.1159/000297717","DOIUrl":"https://doi.org/10.1159/000297717","url":null,"abstract":"<p><p>The high-mobility group A (HMGA) protein family includes HMGA1a, HMGA1b and HMGA1c, which are encoded by the same gene through alternative splicing, and the closely related HMGA2 protein. HMGA proteins have been found to be abundant in several malignant neoplasias, including colorectal, prostate, cervical, lung, thyroid and breast carcinoma. HMGA proteins can be ideal candidates for the identification of new prognosis and diagnosis factors with non-invasive methods. To provide some clarity regarding the abundance of articles on this topic, here we focus on the relationship between HMGA proteins and breast cancer and their clinical perspective in the development of new therapeutic strategies.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"81-85"},"PeriodicalIF":2.1,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000297717","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40073339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}